
Kimberly Chew
Professional Bio
Kimberly is a seasoned professional with a rich background in biotech research, leveraging her extensive experience to guide clients through the intricate landscape of clinical trials and academic research compliance.
As the co-founder and co-lead of the firm’s Psychedelic and Emerging Therapies practice group, Kimberly is particularly inspired by the potential of psychedelic therapeutics to address mental health conditions like PTSD. She skillfully navigates the legal intricacies surrounding these therapies, providing guidance through the clinical trial process at both state and federal levels.
You Can See Everything: Shareholder Litigation Risks from AI in Clinical Trials
Healthcare Law Insights ·
Dealmaking in the Age of AI: IP, Licensing, and Spin-Out Strategies for AI-Enhanced Drug Discovery
Healthcare Law Insights ·
Protocol Design and Recruitment Risks: AI’s Hidden Compliance Traps in Clinical Trials
Healthcare Law Insights ·
Before AI Meets Your Biobank: Five Must-Do Steps for Research Institutions
Healthcare Law Insights ·